Advertisement
ARWR vs IONS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and IONS is a StrongBuy.
ARWR in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 13, 2026
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 38 cases where ARWR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARWR's RSI Oscillator exited the oversold zone, 17 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where ARWR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on October 19, 2026. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in 29 of 42 cases over the following month. The odds of a continued upward trend are 69%.
Following a +5.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in 222 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARWR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.708) is normal, around the industry mean (2.973). P/E Ratio (-25.596) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IONS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for IONS turned positive on October 02, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IONS's RSI Oscillator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on IONS as a result. In 73 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 191 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 65 cases where IONS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for IONS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.594) is normal, around the industry mean (2.973). P/E Ratio (-12.618) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ARWR | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 98 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 77 | |
P/E GROWTH RATING 1..100 | 98 | 23 | |
SEASONALITY SCORE 1..100 | n/a | 31 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARWR's Valuation (82) in the Biotechnology industry is in the same range as IONS (84). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as ARWR (100). This means that IONS’s stock grew similarly to ARWR’s over the last 12 months.
ARWR's SMR Rating (98) in the Biotechnology industry is in the same range as IONS (99). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
ARWR's Price Growth Rating (63) in the Biotechnology industry is in the same range as IONS (77). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
IONS's P/E Growth Rating (23) in the Biotechnology industry is significantly better than the same rating for ARWR (98). This means that IONS’s stock grew significantly faster than ARWR’s over the last 12 months.
| ARWR | IONS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 69% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 68% |
| Momentum ODDS (%) | N/A | 1 day ago 72% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 66% |
| Advances ODDS (%) | 3 days ago 81% | 3 days ago 68% |
| Declines ODDS (%) | 1 day ago 85% | 1 day ago 64% |
| BollingerBands ODDS (%) | 1 day ago 82% | N/A |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARWR’s FA Score shows that 0 FA rating(s) are green while IONS’s FA Score has 1 green FA rating(s).
- ARWR’s FA Score: 0 green, 5 red.
- IONS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARWR’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).
- ARWR’s TA Score: 5 bullish, 2 bearish.
- IONS’s TA Score: 4 bullish, 3 bearish.
Price Growth
ARWR (@Biotechnology) experienced а -0.24% price change this week, while IONS (@Biotechnology) price change was -0.48% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
ARWR is expected to report earnings on Nov 24, 2026.
IONS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ERET | 27.49 | 0.28 | +1.01% |
| iShares Environmentally Aware Real Estate ETF (ERET) | |||
| XJR | 49.03 | 0.39 | +0.80% |
| iShares ESG Select Screened S&P Small-Cap ETF (XJR) | |||
| EMB | 91.85 | 0.41 | +0.45% |
| iShares JP Morgan USD Emerging Markets Bond ETF (EMB) | |||
| QQH | 82.63 | -3.15 | -3.67% |
| HCM Defender 100 Index ETF (QQH) | |||
| IBAT | 36.50 | -1.48 | -3.90% |
| iShares Energy Storage & Materials ETF (IBAT) | |||